Themis Medicare Ltd.
NSE: THEMISMED · Pharmaceuticals · sector
₹91.37NSE close 2026-10-26
Key numbers
Market cap₹842 cr
Price₹91.37
52w high / low₹141 / ₹65
P/E21.1xSector median 27.9x
P/B2.1xSector median 2.9x
Book value₹43.3
Dividend yield0.55%Sector median 0.48%
ROE10.0%Sector median 11.7%
ROCE9.8%Sector median 12.3%
OPM15.1%Sector median 14.0%
Debt / equity0.25xSector median 0.16x
EV/EBITDA18.6xSector median 18.6x
Interest cover4.4x
Current ratio1.84x
Sales growth 3y-1.1%Sector median +9.6%
Profit growth 3y-72.8%Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹9 cr vs borrowings ₹100 cr (FY26): borrowings are higher by ₹91 cr.
- Operating profit covered interest 4.4x in the last 12 months.
- 45.82% of the promoters' shares are pledged (30.8% of all shares).
- Operating cash flow was below net profit in 4 of the last 5 years (FY26, FY24, FY23, FY22).
- Net loss in 3 of the last 8 quarters.
- Revenue was higher than a year earlier in 1 of the last 4 quarters.
- Other income was 23% of net profit in the last 12 months.
- Debtor days went from 170 (FY24) to 190 (FY26).
- Dividend paid in 5 of the last 5 financial years.
- Price ₹91.37 on 2026-10-26: -35.0% from the 52-week high, +40.7% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹287.70 · low ₹71.12
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 117 | 94 | 72 | 98 | 78 | 90 | 77 | 87 |
| EBITDA | 17 | 9 | -6 | -10 | -3 | 9 | 4 | 41 |
| OPM % | 14.6% | 9.1% | -8.1% | -10.3% | -4.0% | 9.9% | 4.9% | 46.6% |
| Other income | 1 | 1 | 2 | 1 | 3 | 1 | 4 | 1 |
| Net profit | 14 | 1 | -10 | -14 | -4 | 10 | 9 | 25 |
| EPS (₹) | 1.55 | 0.06 | -1.05 | -1.54 | -0.39 | 1.10 | 0.96 | 2.67 |
| Revenue YoY | -33.3% | -3.9% | +6.7% | -10.9% | ||||
| Profit YoY | -125.3% | +1,840.4% | – | – |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 395 | 354 | 382 | 406 | 342 | 332 |
| EBITDA | 96 | 67 | 52 | 49 | -0 | 50 |
| Net profit | 73 | 57 | 44 | 30 | 1 | 40 |
| EPS (₹) | 79.22 | 61.83 | 4.73 | 3.24 | 0.12 | 4.34 |
| Revenue growth | -10.2% | +7.7% | +6.2% | -15.6% | -12.8% | |
| Profit growth | -21.9% | -23.5% | -31.5% | -96.2% | – | |
| Dividend / share (₹) | 4.30 | 5.00 | 5.00 | 0.50 | 0.50 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | -1.2% | +8.2% | -12.8% |
| Net profit | -72.8% | -49.7% | – |
| EPS | -87.5% | -68.5% | – |
| Share price | – | -39.9% (2y) | -25.1% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 339 | 378 | 403 | 399 |
| Borrowings | – | 92 | 96 | 83 | 100 |
| Cash & equivalents | – | 19 | 19 | 13 | 9 |
| Total assets | – | 514 | 566 | 588 | 598 |
| Fixed assets | – | 161 | 168 | 172 | 166 |
| Capital work in progress | – | 3 | 3 | 3 | 2 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 145 | 178 | 177 | 178 |
| Inventory | – | 69 | 71 | 84 | 81 |
| Payables | – | 40 | 47 | 51 | 51 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 34 | 16 | 14 | 35 | -3 |
| Cash from investing | -15 | -24 | -16 | -12 | -3 |
| Cash from financing | -18 | 0 | -1 | -26 | 4 |
| Capex | 20 | 29 | 18 | 15 | 5 |
| Free cash flow | 14 | -13 | -4 | 19 | -8 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 16.8% | 11.5% | 7.4% | 0.3% |
| ROCE % | – | 15.9% | 9.3% | 9.0% | -0.3% |
| Debtor days | – | 149 | 170 | 159 | 190 |
| Inventory days | – | 213 | 188 | 233 | 229 |
| Payable days | – | 123 | 126 | 142 | 143 |
| Cash conversion cycle (days) | – | 239 | 232 | 250 | 276 |
| Working capital days | – | 129 | 132 | 133 | 148 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 67.11% |
| FIIs | 0.01% |
| DIIs | 0.01% |
| of which Mutual funds | 0.00% |
| Public (non-institutions) | 32.87% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 67.15% | 67.15% | 67.15% | 67.15% | 67.11% | 67.11% | 67.11% | 67.11% |
| Promoter group | % |
|---|---|
| Dinesh Shantilal Patel, Jayshree Dinesh Patel, Sachin Dinesh Patel (Trustees of Vividhmargi Trust) | 27.49% |
| Vividhmargi Investments PVT | 26.52% |
| Gedeon Richter Investment Management Ltd. | 9.60% |
| Nysha Rupen Choksi | 1.28% |
| Anay Rupen Choksi | 1.28% |
| Shantilal Dahyabhai Patel HUF | 0.61% |
| Dinesh Shantilal Patel | 0.33% |
| Rupen Ashwin Choksi | 0.00% |
| Sachin Dinesh Patel | 0.00% |
| Jayshree D Patel | 0.00% |
| Reena S Patel | 0.00% |
| Public holders above 1% | % |
|---|---|
| Anuj Anantrai Sheth | 3.80% |
| Zafar Ahmadullah | 2.11% |
| ZA Capital Services India Private Ltd | 1.53% |
| L7 Hitech Private Limited | 1.08% |
20,126 shareholders. Pledged: 45.82% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| THEMISMED | ₹842 cr | 21.1x | 2.1x | 10.0% | 9.8% | 15.1% | -1.1% | 0.55% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-09-23 | Dividend | Dividend - Re 0.50 Per Share |
| 2025-09-04 | Dividend | Dividend - Re 0.50 Per Share |
| 2024-07-12 | Dividend | Annual General Meeting/Dividend - Rs 0.50 Per Share |
| 2023-10-10 | Split | Face Value Split (Sub-Division) - From Rs 10/- Per Share To Re 1/- Per Share |
| 2023-09-01 | Dividend | Annual General Meeting/Dividend - Rs 5 Per Share |
| 2022-09-08 | Dividend | Annual General Meeting/Dividend - Rs 5 Per Share |
| 2021-09-08 | Dividend | Annual General Meeting/Dividend - Rs 4.30 Per Share |
| 2020-09-17 | Dividend | Annual General Meeting/Dividend - Rs 1.75 Per Share |
| 2019-08-19 | Other | Annual General Meeting |
| 2018-08-30 | Other | Annual General Meeting |
| 2017-09-19 | Other | Annual General Meeting |
| 2016-09-06 | Other | Annual General Meeting |
| 2015-09-11 | Other | Annual General Meeting |
| 2014-09-19 | Other | Annual General Meeting |
| 2013-08-21 | Other | Annual General Meeting |
| 2011-07-20 | Dividend | Annual General Meeting And Dividend Rs.3/- Per Share |
| 2010-06-16 | Dividend | Annual General Meeting And Dividend Rs.3/- Per Share |
| 2009-12-01 | Other | Annual General Meeting |
| 2008-08-01 | Dividend | Agm/Dividend - 25% |
| 2007-09-14 | Dividend | Agm/Dividend-20% |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Manufacture of Pharmaceuticals & Medicinal Chemicals: Manufacturing and marketing of finished formulations and synthetic Active Pharmaceutical Ingredients (APIs)
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | THEMISMED |
| BSE code | 530199 |
| ISIN | INE083B01024 |
| Face value | ₹1.0 |
| Incorporated | 1969-05-31 |
| Website | www.themismedicare.com |
| Plants (India / abroad) | 3 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.